Assessing PROCEPT BioRobotics (PRCT) Valuation As Fresh Analyst Downgrade Meets Confident Long-Term Growth Views

Simply Wall St.01-11

PROCEPT BioRobotics (PRCT) is back in focus after a flurry of analyst updates, including a downgrade from Bank of America that sits alongside more optimistic views on future utilization and long-term ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602327534?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","is_english":true,"pubTime":"2026-01-11 06:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602327534","market":"sg","top_or_hot":-1,"title":"Assessing PROCEPT BioRobotics (PRCT) Valuation As Fresh Analyst Downgrade Meets Confident Long-Term Growth Views","media":"Simply Wall St.","content":"<div>\n<p>PROCEPT BioRobotics (PRCT) is back in focus after a flurry of analyst updates, including a downgrade from Bank of America that sits alongside more optimistic views on future utilization and long-term ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/assessing-procept-biorobotics-prct-valuation-as-fresh-analys\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing PROCEPT BioRobotics (PRCT) Valuation As Fresh Analyst Downgrade Meets Confident Long-Term Growth Views</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing PROCEPT BioRobotics (PRCT) Valuation As Fresh Analyst Downgrade Meets Confident Long-Term Growth Views\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-11 06:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/assessing-procept-biorobotics-prct-valuation-as-fresh-analys><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PROCEPT BioRobotics (PRCT) is back in focus after a flurry of analyst updates, including a downgrade from Bank of America that sits alongside more optimistic views on future utilization and long-term ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/assessing-procept-biorobotics-prct-valuation-as-fresh-analys\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRCT","symbol_name":"PROCEPT BioRobotics","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/assessing-procept-biorobotics-prct-valuation-as-fresh-analys","article_id":"2602327534","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/assessing-procept-biorobotics-prct-valuation-as-fresh-analys","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602327534","pubTimestamp":1768083643,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"PROCEPT BioRobotics (PRCT) is back in focus after a flurry of analyst updates, including a downgrade from Bank of America that sits alongside more optimistic views on future utilization and long-term market potential.\nSee our latest analysis for PROCEPT BioRobotics.\nThe recent analyst flurry comes after a choppy stretch for PROCEPT BioRobotics, with a 7 day share price return of 6.73% following a 1 day decline of 4.79% and a 1 year total shareholder return of 62.20% in the red. This suggests...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"translate_title":"评估PROCEPT BioRobotics(PRCT)的估值，因为新的分析师降级符合自信的长期增长观点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRCT":1.5},"content_text":"PROCEPT BioRobotics (PRCT) is back in focus after a flurry of analyst updates, including a downgrade from Bank of America that sits alongside more optimistic views on future utilization and long-term market potential. See our latest analysis for PROCEPT BioRobotics. The recent analyst flurry comes after a choppy stretch for PROCEPT BioRobotics, with a 7 day share price return of 6.73% following a 1 day decline of 4.79% and a 1 year total shareholder return of 62.20% in the red. This suggests near term momentum is rebuilding while longer term holders remain deeply underwater. If you are looking beyond a single MedTech name, this could be a useful moment to scan other healthcare opportunities using our screener for healthcare stocks. So with PROCEPT BioRobotics still loss making, trading at US$32.83 and sitting at more than a 50% discount to the average analyst target of US$50.73, is this a mispriced growth story, or is the market already discounting those expectations? AdvertisementMost Popular Narrative: 35.3% Undervalued Compared with the last close of US$32.83, the most followed narrative anchors PROCEPT BioRobotics at a fair value of about US$50.73, framing a sizable gap that rests on ambitious growth and margin assumptions. Ongoing positive clinical trial progress (including WATER IV for prostate cancer) and anticipated future approvals for new indications will expand the total addressable market, which in turn may support higher system placements, greater procedure volumes, and improved long-run profitability as new patient populations are reached. Read the complete narrative. Curious what kind of revenue runway and margin shift would need to line up to support that valuation gap? The narrative focuses on rapid top line expansion, a meaningful swing in profitability, and a premium future earnings multiple that is positioned above the broader medical equipment group. Want to see how those moving parts are modeled together to reach that fair value? Result: Fair Value of $50.73 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the whole setup still hinges on Aquablation keeping its edge, while ongoing operating losses and potential regulatory or reimbursement shifts could quickly flip sentiment on those growth assumptions. Find out about the key risks to this PROCEPT BioRobotics narrative. Another Angle on Value Analysts see PROCEPT BioRobotics trading below their targets, but the P/S ratio tells a more cautious story. At 6.1x sales, compared with a fair ratio of 3.6x and an industry average of 3.3x, the stock screens as expensive. Is the market already pricing in a lot of that growth narrative? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:PRCT P/S Ratio as at Jan 2026 Build Your Own PROCEPT BioRobotics Narrative If this view does not quite fit your own, or you would rather test the numbers firsthand, you can build a custom story in minutes with Do it your way. A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If you are serious about tightening up your process, consider scanning whole groups of ideas built around clear fundamentals rather than stopping at a single stock.  Target potential mispricings by reviewing these 877 undervalued stocks based on cash flows that line up strong cash flow profiles with prices that may not fully reflect them. Spot emerging themes in machine learning and automation by tracking these 28 AI penny stocks that sit at the center of real-world adoption. Build your income watchlist faster by focusing on these 12 dividend stocks with yields > 3% that offer yields above 3% and may warrant further research.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602327534","isCrawlerRequest":true}